Cancer-Focused Biotech Co. Plans $132M IPO In Cold Market
Cancer-focused therapy developer Arcellx Inc. on Monday set a price range on an estimated $132 million initial public offering, guided by Wilson Sonsini Goodrich & Rosati PC and underwriters counsel WilmerHale,...To view the full article, register now.
Already a subscriber? Click here to view full article